Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Olivıer Turrini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2144-2380; OpenAlex author ID A5049257648. Sources: OpenAlex.

Their work

Papers
50 (first author 7, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
110
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 1 paper · 2014: 2 papers · 2015: 7 papers · 2016: 5 papers · 2017: 5 papers · 2018: 3 papers · 2019: 3 papers · 2020: 4 papers · 2021: 4 papers · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 3 papers · 2026: 3 papers

Papers 50

  1. Surgery for Locally Advanced Pancreatic Cancer: Oncological Landmarks for Venous and Arterial Reconstruction. Co-author DOI 10.1245/s10434-025-18768-7↗
  2. ASO Visual Abstract: Surgery for Locally Advanced Pancreatic Cancer: Oncological Landmarks for Venous and Arterial Reconstruction. Co-author DOI 10.1245/s10434-025-19023-9↗
  3. ASO Author Reflections: Arterial Reconstruction in Pancreatic Cancer: Shifting from Anatomical Feasibility Towards Biological Selection. Co-author DOI 10.1245/s10434-026-19469-5↗
  4. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  5. Carbohydrate Antigen 19-9 Delta Function for Survival Prediction in Borderline Pancreatic Cancer. A PANC-PALS Consortium International Multicenter Derivation a… Co-author DOI 10.1097/sla.0000000000006735↗
  6. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  7. Influence of pancreatic fistula on survival after upfront pancreatoduodenectomy for pancreatic ductal adenocarcinoma: multicentre retrospective study. Co-author DOI 10.1093/bjsopen/zrae125↗
  8. Impact on survival of sarcopenia, systemic inflammatory response and anthropometric factors after pancreatectomy for resectable pancreatic adenocarcinoma. Co-author DOI 10.1186/s12957-024-03510-6↗
  9. Development of a Composite Score Based on Carbohydrate Antigen 19-9 Dynamics to Predict Survival in Carbohydrate Antigen 19-9-Producing Patients With Pancreati… Co-author DOI 10.1200/po.24.00193↗
  10. ASO Author Reflections: How to Tackle the Vascular Risk of Celiac Axis Resection for Pancreatic Cancer? First author DOI 10.1245/s10434-023-13422-6↗
  11. Management and outcomes of brain metastases from pancreatic adenocarcinoma: a pooled analysis and literature review. Co-author DOI 10.3389/fonc.2023.1326676↗
  12. Local Ablative Therapy Associated with Immunotherapy in Locally Advanced Pancreatic Cancer: A Solution to Overcome the Double Trouble?-A Comprehensive Review. First author DOI 10.3390/jcm11071948↗
  13. A Novel Pancreatic Fistula Risk Score Including Preoperative Radiation Therapy in Pancreatic Cancer Patients. Co-author DOI 10.1007/s11605-020-04600-y↗
  14. Does pre-operative embolization of a replaced right hepatic artery before pancreaticoduodenectomy for pancreatic adenocarcinoma affect postoperative morbidity … First author DOI 10.1016/j.hpb.2021.04.003↗
  15. Laser Treatment of Pancreatic Cancer with Immunostimulating Interstitial Laser Thermotherapy Protocol: Safety and Feasibility Results From Two Phase 2a Studies. Last author DOI 10.1016/j.jss.2020.10.027↗
  16. Prospective Evaluation of Resection Margins Using Standardized Specimen Protocol Analysis among Patients with Distal Cholangiocarcinoma and Pancreatic Ductal A… Last author DOI 10.3390/jcm10153247↗
  17. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen. Last author DOI 10.1016/j.ejso.2020.02.037↗
  18. Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2019.12.001↗
  19. Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study. Last author DOI 10.1186/s12885-020-6690-1↗
  20. Has the non-resection rate decreased during the last two decades among patients undergoing surgical exploration for pancreatic adenocarcinoma? Last author DOI 10.1186/s12893-020-00835-3↗
  21. Outcomes of pancreatic adenocarcinoma that was not resected because of isolated para-aortic lymph node involvement. Last author DOI 10.1016/j.jviscsurg.2018.06.014↗
  22. Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma. Last author DOI 10.1186/s12957-019-1637-1↗
  23. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRE… First author DOI 10.1245/s10434-018-6931-6↗
  24. Severe postoperative complications decrease overall and disease free survival in pancreatic ductal adenocarcinoma after pancreaticoduodenectomy. Co-author DOI 10.1016/j.ejso.2018.03.024↗
  25. Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes. First author DOI 10.1016/j.suronc.2018.07.014↗
  26. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Co-author DOI 10.1038/s41467-018-04383-6↗
  27. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Co-author DOI 10.1016/j.celrep.2017.11.003↗
  28. Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment?… Last author DOI 10.1016/j.ejso.2017.06.011↗
  29. Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.1097/md.0000000000006544↗
  30. Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individua… Co-author DOI 10.15252/emmm.201606975↗
  31. Venous Resection in Pancreatic Ductal Adenocarcinoma: Impact of Surgical Experience on Early Postoperative Courses. First author DOI 10.21873/anticanres.11811↗
  32. Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients. Co-author DOI 10.1007/s12029-015-9774-4↗
  33. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. Co-author DOI 10.18632/oncotarget.10776↗
  34. Prognostic value of PDL1 expression in pancreatic cancer. Co-author DOI 10.18632/oncotarget.11685↗
  35. Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis-a case control study. Co-author DOI 10.18632/oncotarget.9861↗
  36. Expression of Genes with Copy Number Alterations and Survival of Patients with Pancreatic Adenocarcinoma. Co-author PMID 27107061↗
  37. Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ajpath.2014.11.029↗
  38. Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the Associati… Co-author DOI 10.1245/s10434-014-4304-3↗
  39. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-… Co-author DOI 10.1245/s10434-015-4783-x↗
  40. Targeting CD44 as a novel therapeutic approach for treating pancreatic cancer recurrence. Co-author DOI 10.18632/oncoscience.172↗
  41. A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. Co-author DOI 10.18632/oncotarget.2685↗
  42. Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.3510↗
  43. [Management of localized, locally advanced and metastatic pancreatic adenocarcinoma]. First author PMID 26016202↗
  44. Pancreatic cancer-induced cachexia is Jak2-dependent in mice. Co-author DOI 10.1002/jcp.24580↗
  45. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. Co-author DOI 10.1111/hpb.12061↗
  46. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Co-author DOI 10.1073/pnas.1219555110↗
  47. Homotypic cell cannibalism, a cell-death process regulated by the nuclear protein 1, opposes to metastasis in pancreatic cancer. Co-author DOI 10.1002/emmm.201201255↗
  48. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic … Co-author DOI 10.1093/annonc/mds135↗
  49. Current knowledge on pancreatic cancer. Co-author DOI 10.3389/fonc.2012.00006↗
  50. Genome profiling of pancreatic adenocarcinoma. Co-author DOI 10.1002/gcc.20870↗

Closest collaborators

The 25 strongest of 110 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jonathan Garnier · 20 shared papers, 2016–2026 · strength 3.54
  2. Jean‐Robert Delpéro · 27 shared papers, 2011–2021 · strength 2.09
  3. Marine Gilabert · 22 shared papers, 2012–2023 · strength 1.65
  4. Anaïs Palen · 5 shared papers, 2021–2026 · strength 1.33
  5. Ugo Marchèse · 9 shared papers, 2019–2021 · strength 1.03
  6. Marc F. Giovannini · 15 shared papers, 2011–2020 · strength 0.90
  7. Jean‐Luc Raoul · 13 shared papers, 2012–2018 · strength 0.70
  8. Christopher Lee Wolfgang · 3 shared papers, 2024–2026 · strength 0.69
  9. Juan Iovanna · 14 shared papers, 2011–2018 · strength 0.58
  10. Alain Sauvanet · 6 shared papers, 2014–2024 · strength 0.52
  11. L. Chiche · 5 shared papers, 2015–2024 · strength 0.49
  12. Laurence Moureau-Zabotto · 6 shared papers, 2012–2020 · strength 0.49
  13. António Sá Cunha · 5 shared papers, 2015–2024 · strength 0.42
  14. Christophe Laurent · 4 shared papers, 2015–2024 · strength 0.42
  15. Pauline Duconseil · 8 shared papers, 2015–2019 · strength 0.40
  16. Nelson Dusetti · 9 shared papers, 2013–2018 · strength 0.39
  17. Mehdi Ouaïssi · 8 shared papers, 2015–2017 · strength 0.38
  18. Daniel Brock Hewitt · 2 shared papers, 2024–2025 · strength 0.36
  19. Kelly J. Lafaro · 2 shared papers, 2024–2025 · strength 0.36
  20. Richard Andrew Burkhart · 2 shared papers, 2024–2025 · strength 0.36
  21. Joseph R. Habib · 2 shared papers, 2024–2025 · strength 0.36
  22. Greg D. Sacks · 2 shared papers, 2024–2025 · strength 0.36
  23. Ammar A. Javed · 2 shared papers, 2024–2025 · strength 0.36
  24. Marc G. Besselink · 1 shared paper, 2026 · strength 0.33
  25. Céline Loncle · 8 shared papers, 2012–2017 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.